Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells

Nucleic Acids Research

Volumn 37, Issue 9, 2009, Pages 3094-3109

  Zhou, Jiehua ^a   Swiderski, Piotr ^b   Li, Haitang ^a   Zhang, Jane ^c   Neff, C Preston ^a   Akkina, Ramesh ^a   Rossi, John J ^a,c  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Beckman Research Institute of City of Hope   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DICER; GLYCOPROTEIN GP 120; INTERFERON; RNA APTAMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DESIGN; GENE DELIVERY SYSTEM; GENE LIBRARY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INTERNALIZATION; LYMPHOCYTE CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RNA ISOLATION; SYNTHESIS; T LYMPHOCYTE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 66249129385     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkp185     Document Type: Article

References (53)

1. Dalgleish, A.G., Beverley, P.C., Clapham, P.R., Crawford, D.H., Greaves, M.F. and Weiss, R.A. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 312 763-767.
2. Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J.C. and Montagnier, L. (1984) T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature, 312, 767-768.
3. Sattentau, Q.J. and Moore, J.P. (1993) The role of CD4 in HIV binding and entry. Philos. Trans. R Soc Lond. B Biol. Sci., 342, 59-66.
4. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J. and Hendrickson, W.A. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 393, 648-659.
5. Ugolini, S., Mondor, I. and Sattentau, Q.J. (1999) HIV-1 attachment: another look. Trends Microbiol., 7, 144-149.
6. Wyatt, R. and Sodroski, J. (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science, 280, 1884-1888.
7. Chan, D.C. and Kim, P.S. (1998) HIV entry and its inhibition. Cell 93, 681-684.
8. Blair, W.S., Lin, P.F., Meanwell, N.A. and Wallace, O.B. (2000) HIV-1 entry - an expanding portal for drug discovery. Drug Discov. Today 5, 183-194.
9. Cooley, L.A. and Lewin, S.R. (2003) HIV-1 cell entry and advances in viral entry inhibitor therapy. J. Clin. Virol., 26, 121-132.
10. Kilby, J.M. and Eron, J.J. (2003) Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med., 348, 2228-2238.
11. Pomerantz, R.J. and Horn, D.L. (2003) Twenty years of therapy for HIV-1 infection. Nat. Med., 9, 867-873.
12. Moore, J.P. and Doms, R.W. (2003) The entry of entry inhibitors: A fusion of science and medicine. Proc. Natl Acad. Sci. USA, 100 10598-10602.
13. Jiang, S., Zhao, Q. and Debnath, A.K. (2002) Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des., 8, 563-580.
14. Pierson, T.C. and Doms, R.W. (2003) HIV-1 entry inhibitors: New targets, novel therapies. Immunol. Lett., 85, 113-118.
15. Meanwell, N.A. and Kadow, J.F. (2003) Inhibitors of the entry of HIV into host cells. Curr. Opin. Drug Discov. Devel., 6, 451-461.
16. Lin, P.F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.F., Wang, H.G., Rose, R., Yamanaka, G. et al. (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl Acad. Sci. USA, 100, 11013-11018.
17. Ryser, H.J. and Fluckiger, R. (2005) Progress in targeting HIV-1 entry. Drug Discov. Today, 10, 1085-1094.
18. Smith, D.H., Byrn, R.A., Marsters, S.A., Gregory, T., Groopman, J.E. and Capon, D.J. (1987) Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science, 238, 1704-1707.
19. Hussey, R.E., Richardson, N.E., Kowalski, M., Brown, N.R., Chang, H.C., Siliciano, R.F., Dorfman, T., Walker, B., Sodroski, J. and Reinherz, E.L. (1988) A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature, 331, 78-81.
20. Daar, E.S., Li, X.L., Moudgil, T. and Ho, D.D. (1990) High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl Acad. Sci. USA, 87, 6574-6578.
21. Schacker, T., Coombs, R.W., Collier, A.C., Zeh, J.E., Fox, I., Alam, J., Nelson, K., Eggert, E. and Corey, L. (1994) The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. J. Infect. Dis., 169, 37-40.
22. Trkola, A., Pomales, A.B., Yuan, H., Korber, B., Maddon, P.J., Allaway, G.P., Katinger, H., Barbas, C.F. III, Burton, D.R., Ho, D.D. et al. (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol., 69, 6609-6617.
23. Allaway, G.P., Davis-Bruno, K.L., Beaudry, G.A., Garcia, E.B., Wong, E.L., Ryder, A.M., Hasel, K.W., Gauduin, M.C., Koup, R.A., McDougal, J.S. et al. (1995) Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses, 11, 533-539.
24. Shearer, W.T., Israel, R.J., Starr, S., Fletcher, C.V., Wara, D., Rathore, M., Church, J., DeVille, J., Fenton, T., Graham, B. et al. (2000) Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J. Infect. Dis., 182, 1774-1779.
25. Jacobson, J.M., Lowy, I., Fletcher, C.V., O'Neill, T.J., Tran, D.N., Ketas, T.J., Trkola, A., Klotman, M.E., Maddon, P.J., Olson, W.C. et al. (2000) Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis., 182, 326-329.
26. Dey, B., Lerner, D.L., Lusso, P., Boyd, M.R., Elder, J.H. and Berger, E.A. (2000) Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J. Virol., 74, 4562-4569.
27. Martin, L., Stricher, F., Misse, D., Sironi, F., Pugniere, M., Barthe, P., Prado-Gotor, R., Freulon, I., Magne, X., Roumestand, C. et al. (2003) Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol., 21 71-76.
28. Khati, M., Schuman, M., Ibrahim, J., Sattentau, Q., Gordon, S. and James, W. (2003) Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J. Virol., 77, 12692-12698.
29. Dey, A.K., Khati, M., Tang, M., Wyatt, R., Lea, S.M. and James, W. (2005) An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol., 79, 13806-13810.
30. Dey, A.K., Griffiths, C., Lea, S.M. and James, W. (2005) Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA, 11, 873-884.
31. Nimjee, S.M., Rusconi, C.P. and Sullenger, B.A. (2005) Aptamers: An emerging class of therapeutics. Annu. Rev. Med., 56, 555-583.
32. Pestourie, C., Tavitian, B. and Duconge, F. (2005) Aptamers against extracellular targets for in vivo applications. Biochimie, 87 921-930.
33. Hicke, B.J. and Stephens, A.W. (2000) Escort aptamers: A delivery service for diagnosis and therapy. J. Clin. Invest., 106, 923-928.
34. Lupold, S.E., Hicke, B.J., Lin, Y. and Coffey, D.S. (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res., 62, 4029-4033.
35. McNamara, J.O. II, Andrechek, E.R., Wang, Y., Viles, K.D., Rempel, R.E., Gilboa, E., Sullenger, B.A. and Giangrande, P.H. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 24, 1005-1015.
36. Chu, T.C., Twu, K.Y., Ellington, A.D. and Levy, M. (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res., 34, e73.
37. Chu, T.C., Marks, J.W. III, Lavery, L.A., Faulkner, S., Rosenblum, M.G., Ellington, A.D. and Levy, M. (2006) Aptamer:tOxin conjugates that specifically target prostate tumor cells. Cancer Res., 66, 5989-5992.
38. Bagalkot, V., Farokhzad, O.C., Langer, R. and Jon, S. (2006) An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl., 45, 8149-8152.
39. Farokhzad, O.C., Jon, S., Khademhosseini, A., Tran, T.N., Lavan, D.A. and Langer, R. (2004) Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res., 64, 7668-7672.
40. Farokhzad, O.C., Cheng, J., Teply, B.A., Sherifi, I., Jon, S., Kantoff, P.W., Richie, J.P. and Langer, R. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA, 103, 6315-6320.
41. Farokhzad, O.C., Karp, J.M. and Langer, R. (2006) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv., 3 311-324.
42. Engels, F.K., Mathot, R.A. and Verweij, J. (2007) Alternative drug formulations of docetaxel: A review. Anticancer Drugs, 18, 95-103.
43. Zhou, J., Li, H., Li, S., Zaia, J. and Rossi, J.J. (2008) Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther., 16, 1481-1489.
44. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510.
45. Ellington, A.D. and Szostak, J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
46. Tuerk, C., MacDougal, S. and Gold, L. (1992) RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl Acad. Sci. USA, 89, 6988-6992.
47. Fitzwater, T. and Polisky, B. (1996) A SELEX primer. Methods Enzymol. 267, 275-301.
48. Brass, A.L., Dykxhoorn, D.M., Benita, Y., Yan, N., Engelman, A., Xavier, R.J., Lieberman, J. and Elledge, S.J. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science, 319, 921-926.
49. Rose, S.D., Kim, D.H., Amarzguioui, M., Heidel, J.D., Collingwood, M.A., Davis, M.E., Rossi, J.J. and Behlke, M.A. (2005) Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res., 33, 4140-4156.
50. Amarzguioui, M., Lundberg, P., Cantin, E., Hagstrom, J., Behlke, M.A. and Rossi, J.J. (2006) Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat. Protocol, 1, 508-517.
51. Collingwood, M.A., Rose, S.D., Huang, L., Hillier, C., Amarzguioui, M., Wiiger, M.T., Soifer, H.S., Rossi, J.J. and Behlke, M.A. (2008) Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides, 18, 187-200.
52. Weiss, C.D. and White, J.M. (1993) Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein. J. Virol., 67, 7060-7066.
53. Vodicka, M.A., Goh, W.C., Wu, L.I., Rogel, M.E., Bartz, S.R., Schweickart, V.L., Raport, C.J. and Emerman, M. (1997) Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology, 233, 193-198.